Poly(ADP-ribose) polymerase-2 is a lipid-modulated modulator of muscular lipid homeostasis by Márton, Judit et al.
Accepted Manuscript
Poly(ADP-ribose) polymerase-2 is a lipid-modulated modulator
of muscular lipid homeostasis
Judit Márton, Mária Péter, Gábor Balogh, Beáta Bódi, Andras
Vida, Magdolna Szántó, Dora Bojcsuk, Laura Jankó, Harjit Pal
Bhattoa, Imre Gombos, Karen Uray, Ibolya Horváth, Zsolt Török,
Balint L. Balint, Zoltán Papp, László Vígh, Péter Bai
PII: S1388-1981(18)30187-2
DOI: doi:10.1016/j.bbalip.2018.07.013
Reference: BBAMCB 58338
To appear in: BBA - Molecular and Cell Biology of Lipids
Received date: 22 January 2018
Revised date: 22 July 2018
Accepted date: 29 July 2018
Please cite this article as: Judit Márton, Mária Péter, Gábor Balogh, Beáta Bódi, Andras
Vida, Magdolna Szántó, Dora Bojcsuk, Laura Jankó, Harjit Pal Bhattoa, Imre Gombos,
Karen Uray, Ibolya Horváth, Zsolt Török, Balint L. Balint, Zoltán Papp, László Vígh, Péter
Bai , Poly(ADP-ribose) polymerase-2 is a lipid-modulated modulator of muscular lipid
homeostasis. Bbamcb (2018), doi:10.1016/j.bbalip.2018.07.013
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
1 
 
 
Poly(ADP-ribose) polymerase-2 is a lipid-modulated modulator of muscular lipid 
homeostasis 
 
Judit Márton1, Mária Péter2, Gábor Balogh2, Beáta Bódi3, Andras Vida1,4, Magdolna Szántó1, 
Dora Bojcsuk5, Laura Jankó1, Harjit Pal Bhattoa6, Imre Gombos2, Karen Uray1, Ibolya 
Horváth2, Zsolt Török2, Balint L Balint5, Zoltán Papp3,7, László Vígh2, Péter Bai1,4,8,* 
 
1Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032, 
Hungary 
2Biological Research Center of the Hungarian Academy of Sciences, Szeged, 6726, Hungary 
3Divison of Clinical Physiology, Faculty of Medicine, University of Debrecen, 4032, Hungary 
4MTA-DE Lendület Laboratory of Cellular Metabolism Research Group, Debrecen, 4032, 
Hungary 
5Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of 
Debrecen, 4032, Hungary 
6Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032, 
Hungary 
7HAS-UD Vascular Biology and Myocardial Pathophysiology Research Group, Hungarian 
Academy of Sciences, Debrecen 4012, Hungary 
8Research Center for Molecular Medicine, Faculty of Medicine, University of Debrecen, 4032, 
Hungary 
 
Running title: PARP2 modulates lipid metabolism 
 
 
*All correspondence regarding this article should be sent to this author at the Department of 
Medical Chemistry, Faculty of Medicine, University of Debrecen, H- 4032 Debrecen, 
Egyetem tér 1, Hungary; Tel: +36 52 412 345; Fax: +36 52 412 566; E-mail: 
baip@med.unideb.hu  
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
2 
 
Abstract 
 
There is a growing body of evidence that poly(ADP-ribose) polymerase-2 (PARP2), although 
originally described as a DNA repair protein, has a widespread role as a metabolic regulator. 
We show that the ablation of PARP2 induced characteristic changes in the lipidome. The 
silencing of PARP2 induced the expression of sterol regulatory element-binding protein-1 
and -2 and initiated de novo cholesterol biosynthesis in skeletal muscle. Increased muscular 
cholesterol was shunted to muscular biosynthesis of dihydrotestosterone, an anabolic 
steroid. Thus, skeletal muscle fibers in PARP2-/- mice were stronger compared to those of 
their wild-type littermates. In addition, we detected changes in the dynamics of the cell 
membrane, suggesting that lipidome changes also affect the biophysical characteristics of 
the cell membrane. In in silico and wet chemistry studies, we identified lipid species that can 
decrease the expression of PARP2 and potentially phenocopy the genetic abruption of 
PARP2, including artificial steroids. In view of these observations, we propose a new role for 
PARP2 as a lipid-modulated regulator of lipid metabolism. 
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Introduction 
 
Poly(ADP-ribose) polymerase-2 (PARP2, ARTD2) is a member of the PARP family [1, 
2]. PARP2 binds to DNA strand breaks or RNA species [3-6] where it is activated. Active 
PARP2 cleaves nicotinamide-adenine dinucleotide (NAD+) to nicotinamide and ADP-ribose, 
and forms poly(ADP-ribose) polymers (PAR) on acceptor proteins [7]. PARylation often 
changes the biochemical properties of proteins [8, 9]. PARP2 is responsible for 10-15% of 
total cellular PARP activity; the remaining activity is mostly due to PARP1 [10, 11].  
Although PARP2 was originally described as a DNA repair/maintenance enzyme [10, 
12], recent studies have widened the scope of its biological roles [8, 9]. Importantly, PARP2 
modulates transcription [13, 14] through interactions with numerous transcription factors 
(PPARs, TTF1, ERα, LXRs, FXRs) [15-17]. Changes in transcription are major drivers behind 
PARP2-mediated phenotypes [11, 14, 16, 18-24]. 
PARP2 was shown to be involved in metabolic regulation, including lipid metabolism 
(reviewed in [25, 26]). The observation that PARP2 was a positive cofactor of PPARγ and 
facilitated fat accumulation in white adipose tissue (WAT) [15] demonstrated the role of 
PARP2 in lipid metabolism for the first time. The deletion of PARP2 disrupts lipid deposition 
in WAT [15]. However, in PARP2 knockout mice, no atopic lipid is deposited in the liver or 
skeletal muscle [18], probably due to increased lipid oxidation, which is detectable at the 
organismal level as decreased respiratory quotient [18]. Increased lipid oxidation stems from 
the induction of sirtuin-1 (SIRT1) expression and activity, resulting in mitochondrial 
biogenesis in the skeletal muscle and liver [18, 21].  
PARP2 also impacts another arch of lipid metabolism through cholesterol biosynthesis 
and lipoprotein metabolism. PARP2 is a repressor of sterol regulatory element binding 
protein-1 (SREBP1) expression [14]. In the absence of PARP2, SREBP1 expression and 
activation increase in the liver, culminating in increased hepatic cholesterol content [14]. 
Interestingly, while the enterohepatic circulation of cholesterol does not change in PARP2-/- 
mice, the systemic circulation of cholesterol is impaired, marked by lower high-density 
lipoprotein levels through decreases in hepatic ATP-binding cassette sub-family A Member 1 
(ABCA1) expression [14]. 
In addition to having these functions, PARP2 had been associated with lipid metabolism 
in a genome-wide association study [27], suggesting that there might be other physiologically 
relevant PARP2-mediated changes in lipid metabolism. Skeletal muscle is a major energy 
expender in humans and is strongly affected by changes in PARP2 expression [18], which 
prompted us to perform a wide-scale assessment of PARP2-mediated changes in skeletal 
muscle lipid metabolism. 
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Results 
 
The silencing or deletion of PARP2 leads to characteristic changes in the lipidome 
As a first step, we validated our models by assessing PARP2 expression in PARP2 
knockout mice [28] and in C2C12 cells in which PARP2 was silenced by lentiviral 
transduction of an shRNA construct [18] (Fig. 1A, Fig. S1). We performed a mass 
spectrometry-based lipidomic screening to detect the lipids involved in cell membrane 
synthesis in the skeletal muscle of PARP2+/+ and PARP2-/- mice, as well as in scPARP2 and 
shPARP2 transfected cells. When we subjected the results to orthogonal partial least 
squares discrimination analysis (OPLS-DA), both scPARP2 and shPARP2 C2C12 cells and 
skeletal muscle samples from PARP2+/+ and PARP2-/- mice were clearly separated (Fig. 1B). 
Validation of the model was performed by permutation tests (n = 1000), which returned good 
predictability: Q2 = 0.84 (p = 0.05) for cells and Q2 = 0.57 (p = 0.002) for skeletal muscles. 
These data suggest deep and characteristic changes in the lipidome due to inhibition of 
PARP2. 
 
The silencing of PARP2 leads to higher muscular cholesterol and anabolic steroid 
content  
As a next step, we compared the steady-state gene expression profile of C2C12 cells 
transfected with scPARP2 or shPARP2 to provide an explanation for the changes in Figure 
1. The analysis revealed the dysregulation of 756 genes, of which 429 were downregulated 
and 327 were upregulated. Gene ontology analysis of the hits revealed the dysregulation of 
genes involved in muscular function and metabolism (Fig. 2A, Table 1). Among these genes, 
we identified increases in the expression of Tnn1, Tnnc, and Tnnt3, which are markers of 
oxidative, type I, slow-twitch fibers in shPARP2 cells. As the deletion of PARP2 is linked to 
increased proportions of type I fibers [18], increased expression of Tnn1, Tnnc, and Tnnt3 
validates our findings. Among the metabolic genes, we identified several [29] lipid 
metabolism-related genes, of which 22 were upregulated (Fig. 2A, Table 1).  
A thorough analysis of the lipid metabolism genes revealed that Srebp1, Srebp2, and 
several of their downstream targets (Cyp7a1, Fdps, Ldlr, Acly, Hmgcr, Acaca, and Scd2) 
were upregulated at the mRNA level in C2C12 cells transfected with shPARP2 compared to 
scPARP2-transfected cells. These same lipid metabolism genes were upregulated in the 
skeletal muscle of PARP2-/- compared to PARP2+/+ male mice (Fig. 2B). Increases in the 
expression of SREBP1 and SREBP2 were dependent on the induction of their promoters, as 
suggested by luciferase reporter assays (Fig. 2C). 
We assessed whether changes in the expression of SREBP target genes after silencing 
of PARP2 are indeed related to changes in SREBP expression. To that end, SREPB1 and 
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SREBP2 were silenced in scPARP2 and shPARP2 C2C12 cells (Fig. 2D, Fig. S2). Silencing 
of SREBP1 and SREBP2 abolished the increased expression of HMGCR (Fig. 2E), pointing 
toward the involvement of both SREBPs in the PARP2-elicited effects. 
SREBP1 and SREBP2 are lipid biosynthetic transcription factors that reside in the 
endoplasmic reticulum and Golgi, bound to scaffold proteins, when in the presence of sterols 
[29]. When cholesterol concentrations decrease, SREBPs undergo proteolytic processing 
and translocate to the nucleus, where they bind to promoters and induce a specific gene set, 
leading to cholesterol biosynthesis and accumulation [29]. We have observed that increases 
in SREBP1 and SREBP2 mRNA levels and their downstream target, HMGCR, result in 
increases in the corresponding proteins in PARP2 knockdown cells and in the gastrocnemius 
muscle of PARP2-/- mice (Fig. 3A, Fig. S3A). Moreover, in cells, the nuclear processed forms 
of SREBP1 and SREBP2 were also increased upon PARP2 silencing (Fig. 3A, Fig. S3A), as 
demonstrated by immunocytochemistry studies showing enhanced accumulation of SREBP1 
and SREBP2 in the nucleus (Fig. 3B). 
The question arose whether proteolytic processing of SREBP1 and SREBP2 would be 
affected by the silencing of PARP2. The expression of the proteins involved in SREBP 
maturation (Insig1a, Scap, Sp1, Sp2) was unaltered between scPARP2 and shPARP2 
C2C12 cells (Fig. 3C). Similarly, treatment of cells with an inhibitor of the proteolytic 
processing of SREBPs, betulin [30], reverted SREBP processing both in scPARP2 and 
shPARP2 C2C12 cells (Fig. 3D, Fig. S3B), suggesting that SREBP processing is unaltered 
when PARP2 is silenced. The enhanced activation of SREBP1 and -2 culminated in 
increased total cholesterol content in both C2C12 cells transfected with shPARP2 and 
skeletal muscle of PARP2-/- male mice (Fig. 3E). 
We next wanted to assess whether muscular cholesterol causes muscular 
steroidogenesis. We measured the expression of steroidogenic enzymes involved in the 
conversion of cholesterol to testosterones (anabolic steroids). Out of the genes we assessed, 
Star, Hsd17b11, Srd5a1, and Srd5a2 were induced in cells or tissues depleted of PARP2 
(Fig. 4A). Increases in the expression of Star and Srd5a1 were dependent on the activation 
of the promoters of these genes as highlighted by luciferase reporter assays (Fig. 4B). Star, 
the commitment enzyme toward steroidogenesis, and 5-α-reductase isoforms, which are at 
the “output end” of steroidogenesis, were induced in the absence of PARP2. Changes in the 
expression of the steroidogenic machinery were translated into changes in muscular 
steroids. Dihydrotestosterone (DHT) levels were higher, whereas androstenedione did not 
change and testosterone levels were lower in the muscles of the PARP2-/- mice (Fig 4C). 
Importantly, these changes were restricted to the muscle, as the expression of key PARP2-
mediated steroidogenic enzymes remained unchanged in the suprarenal gland and testis of 
PARP2-/- mice compared to those of PARP2+/+ mice (Fig. S4A). Serum DHT levels showed a 
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minor decrease (Fig. S4B). Increases in the expression of SREBP-dependent genes and 
anabolic steroids were absent in PARP2-/- female mice (Fig. S4C). 
 
Deletion of PARP2 augmented skeletal muscle contractile function  
Testosterones, especially DHT, have an anabolic effect on skeletal muscle [31], which 
prompted us to assess muscle strength. Force production was monitored under isometric 
conditions in single slow and fast twitch skeletal muscle fibers isolated from two mixed-type 
muscles, the gastrocnemius muscle and the diaphragm, of PARP2+/+ and PARP2-/- male 
mice. Ca2+-independent passive force (Fpassive) was not statistially different in skeletal 
myofibers from PARP2+/+ and PARP2-/- mice (Fig. 5A). Ca2+-dependent active force (Factive) at 
submaximal levels of activation and Ca2+-activated maximal force production (Fmax, pCa 4.75) 
were higher in both muscles of PARP2-/- males compared to those of PARP2+/+ animals, for 
both fast- and slow-twitch fibers (Fig. 5B). For the characterization of Ca2+ sensitivity of 
isometric force production, Factive was normalized to Fmax for each skeletal muscle fiber 
(pCa50). The pCa50 values were significantly higher in fast-twitch fibers of gastrocnemius and 
diaphragm muscles in PARP2-/- mice compared to those of PARP2+/+ mice. (Fig. 5C). Taken 
together, the data show that the loss of PARP2 augmented active force production 
irrespective of muscle fiber type. 
 
Silencing of PARP2 changes lateral diffusion of BODIPY FL-SM 
Complex changes in the lipidome may lead to changes in cell membrane structure. To 
monitor dynamic changes in the plasma membranes, we assessed the lateral diffusion and 
confinement properties of a fluorescent probe, BODIPY FL-SM (a sphingomyelin-derivative 
probe). The diffusion coefficient (D) and confinement time (0) describe the lateral diffusion of 
the probe and the organization of the membrane, respectively, and can be calculated from 
the diffusion law graph [32]. We observed increases in the D and in the 0 for the probe (Fig. 
6A-B), indicating that both the speed and the confinement of the diffusion of the probe were 
higher in the membranes of PARP2-silenced cells. This strongly suggests that the membrane 
dynamics of these cells significantly differ from those of the wild type. 
 
Lipids can modulate the expression of PARP2 
The results described above point to a possible role for PARP2 in the regulation of lipid 
homeostasis. Low PARP2 expression or the loss of PARP2 induced a phenotype 
characterized by lipidome changes and improved muscular contractile function. A recent 
study showed that α-lipoic acid downregulates PARP2 expression [33], suggesting that lipid-
mediated regulatory circles may include changes in PARP2 expression. Lipids frequently 
exert their expression effects through nuclear receptors; therefore, we assessed the existing 
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data on nuclear receptor binding sites to identify transcription factors that could be 
responsible for the binding of these lipid species. We performed a screening for nuclear 
receptors that can serve as lipid sensors and translate changes in the lipid environment into 
gene expression programs. We identified a wide variety of nuclear receptor binding elements 
(half sites or inverted and direct repeats separated by different base pairs-long spacers) on 
the PARP2 gene and in its vicinity. Therefore, we selected publicly available ChIP-seq 
(chromatin immunoprecipitation followed by deep sequencing) data derived from different 
organisms and cell lines to identify which nuclear receptor(s) bind(s) within the examined 
region. We found that upon calcitriol (1,25-(OH)2D3) treatment, the vitamin D receptor (VDR) 
binds to the promoter region of the Parp2 gene in mice and also in the gene body between 
exons 4 and 5. The VDR binding site on the promoter region overlaps with the non-coding 
RNA Rpph1 (also known as H1 RNA), and the summit position of this peak is located ~250 
base pairs upstream of the transcription start site of Parp2 (Fig. 7A). We next treated C2C12 
cells with vitamin D, which increased the mRNA expression of Parp2 and the VDR (Fig. 8A), 
suggesting that the VDR could indeed be the receptor that can physiologically regulate the 
expression of PARP2. Nevertheless, it should be stressed that other, yet unrevealed 
receptors or transcription factors may contribute to the lipid-mediated regulation of PARP2 
mRNA expression. 
We searched the NCBI GEO database for other lipids that potentially modulate the 
expression of PARP2. In addition to α-lipoic acid, we identified steroids, such as 
dexamethasone [34], medroxyprogesterone acetate, tibolone [35], and oxandrolone [36], that 
can downregulate PARP2 expression and potentially induce changes in lipid homeostasis. 
To validate these findings in cell experiments, we treated C2C12 cells with a large set of 
cholesterol derivatives (Table 2) and subsequently assessed the expression of PARP2. Out 
of the compounds used in the experiments, MPA, tibolone, LCA, and DCA were capable of 
downregulating the expression of PARP2 (Fig. 8B). 
  
Discussion 
 
In this study, we provide evidence that decreased PARP2 expression leads to 
widespread changes in lipid metabolism. This is achieved through enhancing SREBP1 and 2 
transcription. SREBPs are central to the control of a variety of lipid biosynthetic pathways, 
including lipid desaturation and phospholipid and sterol biosynthesis [37]. PARP2 may 
induce adaptive responses to dietary/environmental stresses resulting in the maintenance of 
optimal membrane lipid composition, and profoundly affecting the biophysical properties of 
biological membranes.  
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We demonstrate that changes in lipid metabolism involve alterations in cell membrane 
lipid composition and synthesis of cholesterol and DHT that, altogether, strengthen muscular 
output. In addition, we show that some lipids can reduce PARP2 expression and, hence, 
produce changes in lipid metabolism similarly to the genetic deletion of PARP2. 
SREBP1-dependent increases in cholesterol content upon decreased PARP2 
expression have already been shown in the liver. Inhibition of PARP2 expression results in 
beneficial changes to the lipoprotein profile and decreased ABCA1 expression in the liver 
[14]. The current study provides evidence for the involvement of another tissue, skeletal 
muscle, in PARP2-elicited changes in lipid metabolism. 
In addition to PARP2, other PARPs also play a role in cholesterol homeostasis. The 
ablation of PARP1 represses cholesterol efflux in macrophages by repressing LXR, resulting 
in repression of ABCA1 [38]. In hepatocytes, PARP1, together with histone H1.2, is vital for 
the efficient transcription of microsomal epoxide hydrolase (EPHX1), which facilitates bile 
acid export [39]. In addition, PARP1 activation has been linked to steroid-evoked changes 
[40-44]. A recent study suggests that PARP10 regulates lipid oxidation [45]. Apparently, 
PARPs have complex and widespread roles in regulating lipid metabolism. 
The current study suggests that certain lipids can repress the expression of PARP2 and, 
therefore, PARP2 protein levels and activity. The first lipid species shown to inhibit PARP2 
expression was α-lipoic acid [33]. Importantly, decreased PARP2 expression via α-lipoic acid 
had functional consequences, including enhanced SIRT1 activation [33]. Thus, α-lipoic acid 
may be a viable treatment supplement for obesity and type II diabetes [46-48]. Hereby, we 
add a set of cholesterol derivatives (dexamethasone, medroxyprogesterone acetate, 
tibolone, and oxandrolone) that have similar capabilities. These findings add a new modality 
to the regulation of PARP2 besides acetylation [49]. Note that PARP1 has lipid activators (7-
ketocholesterol and fatty acids) [50, 51] and inhibitors (estrogen) [43], moreover, PARP1 
deletion modulates the levels of several lipid species [52]. 
PARP2 has a partial protective effect on oxidative stress-related pathologies [11, 53, 54] 
and metabolic diseases, like obesity, type II diabetes, and hyperlipidemias [14, 18, 21], that 
is due to enhanced SIRT1 expression and the consequent mitochondrial biogenesis. Our 
current findings show that PARP2 has a role in regulating muscle strength and homeostasis; 
therefore, the activation of PARP2 can disrupt intramuscular endocrine homeostasis. Finally, 
as licensed PARP inhibitors block all enzymes in the PARP family, including PARP2 [55], the 
phenotype that we described may be a side effect of these inhibitors. 
 
Materials and methods 
 
Chemicals 
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All chemicals were from Sigma-Aldrich unless stated otherwise. 
 
Cell culture 
PARP2-silenced C2C12 cells were described in [18]. PARP2 knockdown and control 
clones were maintained over generations. C2C12 cells were cultured in DMEM (4500 mg/L 
glucose) (Sigma-Aldrich; Saint Louis, MO, USA) with 10% fetal calf serum (FCS). Cells were 
differentiated in DMEM (4500 mg/L glucose) containing 2% horse serum for 4 days in all 
experiments, except the luciferase reporter assays. 
 
Animal studies 
Homozygous PARP-2−/− and littermate PARP-2+/+ male mice [28] on a C57BL/6J 
background, from heterozygous crossings were used. Animal experiments were approved by 
the Institutional Animal Care and Use Committee at the University of Debrecen and the 
National Board for Animal Experimentation (1/2014 DE MÁB). All animal experiments were 
carried out according to local, national, and EU ethical guidelines. Animal studies are 
reported in compliance with the ARRIVE guidelines [56]. Mice were killed by cervical 
dislocation. No more than six mice were housed in each cage (standard block shape = 365 × 
207 × 140 mm, surface = 530 cm2; 1284 L Eurostandard Type II. L from Techniplast) with 
Lignocel Select Fine (J. Rettenmaier und Söhne, Germany) as bedding. Mice had paper 
tubes to enrich their environment. The dark/light cycle was 12 h, and temperature was 22 ± 1 
°C. Cages were changed once a week, on the same day. Mice had ad libitum access to food 
and water (sterilized tap water). The animal facility was overseen by a veterinarian. 
 
Cholesterol determination 
Lipids were extracted from muscle and C2C12 cell samples by the Folch method, as 
described [57]. A cholesterol kit was used for the cholesterol quantitative determination 
(cholesterol RTU, bioMÉRIEUX; Marcy l'Etoile, France) following the recommendations of 
the manufacturer and adapted to a microplate format.  
 
SDS-PAGE, Western blotting 
Cells and tissues were lysed by RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1 % SDS, 1% 
Nonidet P-40, 1 mM Na3VO3, 1 mM NaF, 0.5% sodium deoxycholate, 1 mM 
phenylmethylsulfonyl fluoride, protease inhibitor mixture; pH 8.0), then boiled with 2x 
Laemmli sample buffer and merkaptoethanol. Proteins were separated by SDS-PAGE on 8% 
acrylamide gels and transferred onto a nitrocellulose membrane (Amersham™ Protran® 
Supported, GE Healthcare; Chicago, IL, USA). Antibodies used in this study are shown in 
Table 4. The secondary antibody was anti-rabbit IgG POD (Sigma-Aldrich; St. Louis, MO, 
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USA). Labelled proteins were detected by an Alpha Innotech FluorChem FC2 device using a 
West Pico ECL Kit (Thermo Fisher Scientific; Walthman, MA, USA). Blots were quantified by 
densitometry using Image J software [58]. 
 
Cell fractionation 
C2C12 cells transfected with scPARP2 or shPARP2 were washed with ice-cold PBS 
buffer and centrifuged at 4 °C at 100 g for 5 min. Pellets were (re)diluted in 4 volumes of 
homogenization buffer (0.5 M sucrose and 20 mM HEPES [pH 7.5]; 1 mM EDTA, 1 mM 
EGTA, protease inhibitors, and 0.5 % Nonidet-P) and were lysed and homogenized by 
aspirating through a 26-G needle 15 times. Lysates were centrifuged at 4 °C at 5000 g for 10 
min. The supernatant was the cytosolic fraction, whereas the pellet was the nuclear fraction. 
To prepare the cytoplasmic fraction, the supernatant was centrifuged again at 8000 g at 4 °C 
for 3 min. The supernatant was used as a cytosolic fraction. To prepare the nuclear fraction, 
the pellet of the 5000-g centrifugation was resuspended in 3 volumes of 0.25 M sucrose, 10 
mM Hepes (pH 7.9), 3.3 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and protease inhibitors and 
was lysed by passing through a 26-G needle 10 times; the lysate was subsequently spun at 
4 °C at 2000 g for 15 min. The pellet was resolubilized in 0.35 M sucrose, 10 mM Hepes (pH 
7.9), 3.3 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and protease inhibitors and was passed 
through a 26-G needle; it was then sonicated on ice (3x15 pulses, 15-s intervals). The 
sonicated suspension was regarded as the nuclear fraction. 
 
Immunohistochemistry and confocal microscopy 
Monolayer cells were grown on coverslips. Cells were washed with PBS and fixed in ice-
cold methanol (air-dried). After fixation, the cells were rehydrated and permeabilized in 1% 
PBSTTX followed by washes with PBS. Cells were incubated in blocking buffer (1 mg/ml 
BSA/PBS) for an hour at room temperature. After the blocking buffer was removed, cells 
were incubated with primery antibodies (SREBP1 1:100; SREBP2 1:100) (Santa Cruz; Santa 
Cruz, CA, USA) in 1 mg/ml BSA/PBS overnight using moist chambers (Table 4.). After the 
overnight incubation, cells were washed three times with PBS. For visualization,the 
secondary antibody, Alexa 488 FITC-conjugated anti-rabbit IgG (1:500) (Life Technologies; 
Carlsbad, CA, USA), was used. Nuclei were counterstained with ToPro-3 (1 µM final 
concentration) (Life Technologies). Cells were incubated with dyes for an hour at room 
temperature. Stained slides were assessed using a Leica TCS SP8 confocal microscope with 
a HC PL APO CS2 63x/1.40 oil immersion objective on a DMI6000 CS microscope. The 
confocal pictures were taken with LAS X 2.0.1.14392. software. Background fluorescence 
was determined from cells incubated with just the secondary antibody.  
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DNA constructs and luciferase activity measurement 
Promoter transactivation was measured using a luciferase reporter assay. Cells were 
plated onto 6-well plates. Lipofectamine 3000 (Invitrogen, Thermo Fisher Scientific; 
Walthman, MA, USA) was used for transfection following the recommendations of the 
manufacturer. Co-transfection was performed with one of the following plasmids (4 µg): 
pGL2-SREBP1c-2600luc [59] for the study of the promoter of SREBP1, pKM2L-phSREBP2 
(from the RIKEN Bioresource Center, Japan) for the study of the promoter of SREBP2, p-966 
Star/hGH (generous gift from Barabara J. Clark; University of Louisville; Louisville, KY, USA) 
[60] for the study of the promoter of StAR, p-Luc-GW-Srd5a2 (-1500/+107) (generous gift 
from Timothy Osborne; Sanford-Burnham Medical Research Institute; Orlando, FL, USA) [61] 
for the study of the promoter of srd5a and 2 µg β-galactosidase expression plasmid (pCMV-
βgal). Luciferase activity was measured by a Victor3 multilabel plate reader and normalized to 
β-galactosidase activity. 
 
siRNA transfections 
C2C12 cells were transfected with 30 nM Silencer Select siRNA (Srebf1, Srebf2; 
Thermo Fisher Scientific; Walthman, MA, USA) using Lipofectamine RNAiMAX transfection 
reagent (Thermo Fisher Scientific) for 48 h.  
 
Microarray experiments and validation 
Total RNA was extracted, using an RNeasy Mini Kit (Qiagen; Hilden, Germany), from 
C2C12 cells transfected with scPARP2 and shPARP2. RNA quality was assessed using 
Agilent Bioanalyser 2100 (Agilent Technologies; Santa Clara, CA, USA). The global 
expression pattern was analyzed on Affymetrix GeneChip Mouse Gene 1.0 ST array. 
Microarray experiments were performed as in [14]. Gene expressions profiles were validated 
by RT-qPCR as described later.  
 
Lipid extraction and mass spectrometry 
The solvents used for extraction and for mass spectrometry analyses were of liquid 
chromatographic grade (Merck; Darmstadt, Germany) and Optima LCMS grade (Thermo 
Fisher Scientific; Bremen, Germany). Lipid standards were obtained from Avanti Polar Lipids 
(Alabaster, AL, USA). All other chemicals were purchased from Sigma-Aldrich (Steinheim, 
Germany) and were of the best available grade. 
For lipid extraction, C2C12 cells were washed twice with cold PBS, collected in 
Eppendorf tubes (6 million cells per tube), and centrifuged. The pellets were sonicated in a 
bath sonicator for 5 min in 1 mL methanol containing 0.001% butylated hydroxytoluene as an 
antioxidant, then shaken for 5 min and centrifuged at 10,000 × g for 5 min. The supernatant 
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was transferred into a new Eppendorf tube and stored at −20 °C. For muscle samples, 
tissues were weighed and disrupted in water using a bullet blender homogenizer (Bullet 
Blender Gold, Next Advance; Location) in the presence of stainless steel beads (0.9-2 mm) 
at speed 10 for 7 min at 4 °C. Lipid extraction was carried out from a portion of the 
homogenate (ca. 10 µL corresponding to 2 mg w/w) in a similar fashion as for cell samples. 
Mass spectrometric analyses were performed on a LTQ-Orbitrap Elite instrument 
(Thermo Fisher Scientific; Bremen, Germany) equipped with a robotic nanoflow ion source 
(TriVersa NanoMate; Advion BioSciences; Ithaca, NY, USA) as described in [62]. Orthogonal 
PLS-DA analyses of lipidomics datasets were performed using MetaboAnalyst [63]. 
 
RT-qPCR 
Total RNA was isolated by Extrazol ready-to-use reagent (Blirt S. A.; Gdańsk, Poland). 
cDNA synthesis and RT-qPCR were performed as described in [14]. Expression was 
normalized to a geometric mean of 18S, cyclophilin or Gapdh. Primers are listed in Table 3. 
 
Mechanical measurements in single permeabilized skeletal myofiber preparations  
Gastrocnemius and diaphragm muscle tissue were obtained from PARP2+/+ and PARP2-
/- male mice. Tissue samples were snap-frozen and kept at -80oC until used. Muscle fibers 
were mechanically isolated from thawed samples in isolating solution (100 mM KCl, 2 mM 
EGTA, 1 mM MgCl2, 4 mM Na2ATP, 10 mM imidazole; pH = 7.0) containing protease 
inhibitors (0.5 mM phenylmethylsulfonyl fluoride [PMSF], 40 μM leupeptin, and 10 μM E-64; 
all from Sigma-Aldrich; St. Louis, MO, USA)) at 4 °C. Muscle fibers were then permeabilized 
with 0.5% Triton X-100 detergent in the above solution for 4 min to remove all membranes. 
Single isolated and skinned muscle fibers were mounted between two stainless insect 
needles with silicone adhesive (DAP 100% all-purpose silicone sealant; Baltimore, MD, USA) 
at 15 °C. The needles were connected to a highly sensitive force transducer (SensoNor; 
Horten, Norway) and an electromagnetic length controller (Aurora Scientific Inc.; Aurora, 
Canada). Activating and relaxing solutions were used during force measurements. The 
activating solution with the highest Ca2+ concentration contained 7 mM Ca2+-EGTA, 37.34 
mM KCl, 10 mM N,N-bis (2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 6.24 mM 
MgCl2, 6.99 mM Na2ATP, 15 mM Na2CrP (pH = 7.2, pCa 4.75) (Ca
2+ concentrations are 
expressed in logarithmic units [pCa]). The relaxing solution contained the same components 
as above except it included EGTA instead of Ca2+-EGTA (pH = 7.2; pCa = 9). Both solutions 
were supplemented with protease inhibitors as above. Solutions with intermediate Ca2+ 
concentrations were prepared by mixing activating and relaxing solutions (pCa = 5.4-7.0). 
Active force (Factive) and Ca
2+-sensitivity to force production (pCa50) were determined in 
activating solutions with different Ca2+ concentrations. When active muscle force reached its 
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maximum, a quick release-restretch maneuver (30 ms) was applied in activating solution. 
Due to this maneuver, force first dropped from the peak isometric level to 0 (total peak 
isometric force, Ftotal) and then it started to redevelop. Fiber type was identified on the basis 
of force redevelopment kinetics following the quick release-restretch maneuvers. Ca2+-
independent passive force (Fpassive) was approximated by shortening the preparations to 80% 
of the original lengths in relaxing solution for 8 s. Active isometric force (Factive) was 
calculated as the difference between Ftotal and Fpassive. Preparations were exposed to a series 
of solutions with intermediate Ca2+ concentrations to construct pCa-force relationships. 
Lastly, preparations were exposed to an activating solution with saturating Ca2+ 
concentration (pCa = 4.75); and if maximal isometric force (Fmax) at this time was less than 
80% of the initial Fmax, the experiment was discarded. Factive at submaximal Ca
2+ levels was 
normalized to Fmax (pCa 4.75, Fmax). The relation between the Factive and pCa was fitted to a 
modified Hill equation: F = Fmax[Ca
2+]nHill/(Ca50
nHill + [Ca2+]nHill) where F was the force at a 
given Ca2+concentration ([Ca2+]), Fmax, nHill and pCa50 denoted the maximal Factive at 
saturating [Ca2+] and the slope and the midpoint of the sigmoidal relationship, respectively. 
Absolute forces (Factive and Fpassive) were normalized to a cross-sectional area and expressed 
in kN/m2. Sarcomere length (SL) was adjusted to 2.3 µm. Ca2+-evoked contractures were 
recorded by a custom-built LABVIEW Data Acquisition platform and analyzed by a LabVIEW 
analyzing software (Myo; National Instruments; Austin, TX, USA). 
 
Muscular steroid hormone extraction and determination 
Steroid extraction was performed similarly to [64]. DHT, testosterone, and 
androstenedione were measured by an RIA kit (Beckman Coulter; Brea, CA, USA). 
Testosterone and androstenedione were determined from whole skeletal muscle of a mouse. 
For the measurement of DHT, a pool of gastrocnemius muscle was used from PARP2 wild-
type and from PARP2 knockout mice; hence, we cannot determine the biological error. 
 
ImFCS 
Cells were seeded into glass bottom dishes (MatTek Corporation; City, MA, USA) a day 
before the experiments. After labeling the cells with fluorescent lipid probe (BODIPY FL C5-
sphingomyelin; Molecular Probes; Eugene, OR, USA) for 8 min at 37 °C, cells were washed 
three times with the culture media. The measurements were performed in culture media 
without phenol red, in a POC-R cell cultivation system (Zeiss; Jena, Germany). This system 
incorporates a controlled objective heater and CO2/air gas chamber. Objective-type TIRF 
illumination was used to achieve the thinnest excited sample volume, with a high numerical 
aperture objective (alpha Plan-FLUAR 100; Zeiss). The data were acquired using a 
ProEM512 EMCCD camera (Princton Instruments; Trenton, NJ, USA) with a 3-ms effective 
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exposure time and a 20 × 40 pixel acquisition area per measurement (pixel size = 0.16 µm). 
The ImFCS plugin for ImageJ software was used for data evaluation 
(http://www.dbs.nus.edu.sg/lab/BFL/imfcs_image_j_plugin.html). Detailed data analysis is 
described in [62]. 
 
Chip-seq reanalysis 
We investigated 32 publicly available ChIP-seq data in nine different human and mouse 
cell types (GEO identifiers and references are in Table 5, 6). The human experiments were 
performed in two lymphoblastoid cell lines (GM10855 and GM10861), in leukemia monocytic 
(THP-1), hepatic stellate (LX2) and prostate cancer (LNCaP) cells. The mouse ChIP-seq 
data were derived from mouse intestinal epithelial cells, from osteoblast precursor (MC3T3-
E1) cell line and from non-differentiated (MSC), osteogenic (MSC osteogenic) or adipogenic 
(MSC adipogenic) differentiation media-treated bone marrow-derived mesenchymal stem 
cells (MSC). 
Raw sequence data were aligned to the mm10 reference genome assembly by using the 
Burrows-Wheeler Alignment (BWA) tool (v0.7.10) [65]. BAM files were generated by SAM 
tools (v0.1.19) [66], and BEDGRAPH files were created by the makeUCSCfile of 
Hypergeometric Optimization of Motif EnRichment (HOMER) tool (v4.2) [67]. Peaks were 
predicted with MACS2 [68], and coverage files were also created by HOMER. 
The equivalent DNA sequences of the Vitamin D response element (VDRE) at human 
PARP1 gene promoter could be identified in 37 different species based on the Comparative 
Genomics data sets of Ensembl database (Archive Ensembl 75: GRCh17.p13). Sequence of 
the VDRE ±10 base pairs was visualized by using BioEdit Sequence Alignment Editor 
(v7.0.5.3) [69].  
 
Database screening 
The GEO (profiles) database of the NCBI was screened for PARP2+steroid and 
PARP2+lipid keywords. 
 
Data availability  
The primary data of the present manuscript are available at 
https://figshare.com/s/3e7866c3ce9db7c4df88. The microarray dataset has been uploaded to 
the Geo database of NCBI at GSE108737. 
 
Statistical analysis 
For the comparison of two groups, we used the two-tailed, unpaired Student’s t-test. p 
values smaller than 0.05 were considered significant. Significance levels were given in the 
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figure captions, actual p values can be found in the primary dataset available online 
(https://figshare.com/s/3e7866c3ce9db7c4df88). Actual p values are given for those 
comparisons, where p is slightly higher than 0.05. 
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Figure legends 
 
Figure 1. Silencing of PARP2 induces changes to the lipidome. 
A. PARP2 levels were determined by RT-qPCR in C2C12 cells transfected with 
scPARP2 or shPARP2 (n = 4, in triplicates) and in the skeletal muscle of PARP2+/+ 
and PARP2-/- male mice (3 months of age, n = 9/8). Protein levels of PARP2 were 
detected by Western blotting in the same cohorts of C2C12 cells and mice. Actin 
was used as a loading control. 
B. OPLS-DA score plots of lipidomic datasets (n = 4 for scPARP2 vs. shPARP2 
C2C12 cells, and n = 12/8 for PARP2+/+ vs. PARP2-/- skeletal muscles). 
All abbreviations are in the text. (A) The two-tailed, unpaired Student’s t-test was used for 
comparisons. *, **, and *** represent statistically significant differences between the 
scPARP2 and shPARP2 C2C12 cells or PARP2+/+ and PARP2-/- mice at p < 0.05, 0.01, and 
0.001, respectively. Averages of values are presented. For cell studies, error is represented 
as ± SD; for murine studies, error is represented as ± SEM. (B) The OPLS-DA model was 
validated by permutation tests. 
 
Figure 2. Silencing of PARP2 induces the expression of SREBP1, SREBP2, and their 
target genes. 
A. Gene expression was analyzed in scPARP2 and shPARP2 C2C12 cells (n = 1, in 
triplicates) using microarray, and genes were selected as a function of their 
biological function.  
B. Microarray data were validated by RT–qPCR using RNA prepared from scPARP2 
and shPARP2 C2C12 cells (n = 3, in triplicates) and RNA prepared from the 
gastrocnemius muscle of PARP2+/+ and PARP2-/- male mice (3 months of age, n = 
8/8). The indicated genes were assessed. 
C. The transactivation of the promoter of SREBP1 and 2 was assessed in luciferase 
reporter assays in scPARP2 and shPARP2 C2C12 cells (n = 3, in duplicates for 
both promoters). 
D-E. SREBP1 and SREBP2 were silenced in scPARP2 and shPARP2 C2C12 cells (n 
= 3/3). Undifferentiated C2C12 cells were transfected with siRNA for 2 days; then 
(D) the indicated proteins were determined by Western blotting, and (E) HMGCR 
mRNA expression was determined by RT-qPCR. 
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All abbreviations are in the text. The two-tailed, unpaired Student’s t-test was used for 
comparisons, except for panel E, where two-way ANOVA with the Tukey post-hoc test was 
used. Statistically significant differences between the scPARP2 and shPARP2 C2C12 cells 
or PARP2+/+ and PARP2-/- mice are represented as *, **, and *** for p < 0.05, 0.01, and 
0.001, respectively. Average values are presented, and error is represented as ± SEM. 
 
Figure 3. Silencing of PARP2 activates SREBP1 and SREBP2. 
A. In C2C12 cells transfected with scPARP2 and shPARP2 (n = 3/3; left side) and in 
the gastrocnemius muscle of PARP2+/+ and PARP2-/- male mice (right; 3 months of 
age, n = 7/11), the indicated proteins were assessed by Western blotting. Actin was 
used as a loading control. Representative blots are presented. 
B. The cellular localizations of SREBP1 and SREBP2 were assessed by fluorescence 
immunocytochemistry and confocal microscopy in scPARP2 and shPARP2 C2C12 
cells (n = 1, 9/9 cells were assessed). One characteristic sample is shown. The 
ratio between the nuclear and extranuclear SREBP1 and 2 was calculated. Scale 
bar: . 
C. The expressions of the indicated genes were measured by qRT-qPCR in the 
mRNA pool of scPARP and shPARP2 C2C12 cells (n = 2). 
D. In scPARP2 and shPARP2 C2C12 cells (n = 1), the expressions of SREBP1 and 
SREBP2 were assessed after 48 h of treatment with 10 µg/ml betulin. 
E. Cholesterol was determined in scPARP2 and shPARP2 C2C12 cells (n = 3/3, in 
triplicates) and in gastrocnemius muscle of PARP2+/+ and PARP2-/- male mice (3 
months of age, n = 7/11). Cholesterol concentration is given as µg cholesterol/mg 
cell pellet for cell samples or µg/mg wet weight for muscles. 
All abbreviations are in the text. The two-tailed, unpaired Student’s t-test was used for 
comparisons. Statistically significant differences between the scPARP2 and shPARP2 
C2C12 cells or PARP2+/+ and PARP2-/- mice are represented as *, **, and *** for p < 0.05, 
0.01, and 0.001, respectively. Average values are presented, and error is represented as ± 
SEM. 
 
Figure 4. Silencing of PARP2 induces anabolic steroid synthesis in the skeletal 
muscle. 
A. mRNA expression levels of Star, Hsd17b11, Srd5a1, and Srd5a2 in scPARP2 and 
shPARP2 C2C12 cells (n = 3, in triplicates) and in gastrocnemius muscle of 
PARP2+/+ and PARP2-/- male mice (3 months of age, n = 13/10) quantified by RT-
qPCR. 
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B. The activity of the Star and Srd5a1 promoter was assessed in scPARP2 and 
shPARP2 C2C12 cells (n = 3/3) using luciferase reporter assays. 
C. Steroid concentrations were measured by RIA assays in skeletal muscle of 
PARP2+/+ and PARP2-/- male mice (3 months of age, n = 18/18). For testosterone 
and androstenedione measurements, all skeletal muscles were harvested from 
mice and extracted. For DHT, the gastrocnemius muscles were harvested from all 
mice in the study. 
All abbreviations are in the text. The two-tailed, unpaired Student’s t-test was used for 
comparisons. Statistically significant differences between the scPARP2 and shPARP2 
C2C12 cells or PARP2+/+ and PARP2-/- mice are represented as *, **, and *** for p < 0.05, 
0.01, and 0.001, respectively. Averages of values are presented, and error is represented as 
± SEM. The values of the DHT levels represent mixtures derived from gastrocnemius 
muscles of PARP2+/+ and PARP2-/- male mice, respectively. Therefore, we did not perform 
statistical analysis. 
 
Figure 5. Genetic deletion of PARP2 augments skeletal muscle fiber strength. 
Skeletal myofibers were isolated from gastrocnemius muscle (left; n = 7/7 for slow-twitch and 
n = 9/7 for fast-twitch fibers, all from different animals) or from the diaphragm (right; n = 3/4 
for slow- and n = 3/3 for fast-twitch fibers, all from different animals) of 3-mo-old PARP2+/+ or 
PARP2-/- male mice. Ca2+-independent passive force (Fpassive) of permeabilized muscle fibers 
was determined in relaxing solution (pCa = 9.0) (A). The upper parts of panel B depict the 
Ca2+-dependence of active force productions (Factive), and bar graphs at the bottom illustrate 
maximal Ca2+-activated active force values (Fmax, pCa = 4.75) in PARP2
+/+ and PARP2-/- male 
mice for the gastrocnemius and diaphragm muscles. To determine the Ca2+-sensitivity of 
force production (pCa50, insets), Factive values at submaximal levels of activations were 
normalized to Fmax (C). All abbreviations are given in the text. The two-tailed, unpaired 
Student’s t-test was used for comparisons. Data are expressed as mean ± SEM. Statistically 
significant differences between the control values vs. calcium treatment are represented as * 
for p < 0.05. Statistically significant differences between muscles of PARP2+/+ and PARP2-/- 
mice are represented as # for p < 0.05. 
 
Figure 6. Silencing of PARP2 modifies the lateral diffusion properties of the SM-probe 
in the plasma membrane. 
In scPARP2 and shPARP2 C2C12 cells, the diffusion of the BODIPY FL-SM probe (n = 36) 
was assessed. The average of D (A) and τ0 values (B) are depicted (± SEM). The two-tailed, 
unpaired Student’s t-test was used for comparisons. Statistical significance between 
scPARP2 and shPARP2 C2C12 cells at p < 0.05 is represented as *. 
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Figure 7. Vitamin D receptor is bound to a vitamin D response element (VDRE) at the 
promoter of PARP2. 
A. Vitamin D receptor (VDR) peaks were identified in available ChIP-seq data as 
described.  
B. VDREs were identified on the promoter of PARP2 in different species. 
 
Figure 8. Lipid species can modulate the expression of PARP2. 
A. C2C12 cells were treated with vitamin D in the concentrations indicated for 48 h; 
then protein levels of PARP2 and VDR were determined by Western blotting (n = 
2).  
B. C2C12 cells were treated with the lipid species in the concentrations indicated for 
48 h; then PARP2 levels were assessed by Western blotting (n = 2). 
The two-tailed, unpaired Student’s t-test was used for comparisons. Data are 
expressed as mean ± SEM; * and ** represent statistical significance at p = 0.05 or 
0.01 between vehicle and drug-treated C2C12 cells, respectively. Abbreviations are in 
Table 2. 
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Table 1. Functional grouping of dysregulated genes in scPARP2 vs. shPARP2 C2C12 
cells. 
Genes with a fold change of 1.5, or larger are shown. *, ** and *** indicate statistically 
significant differences between scPARP2 and shPARP2 cells at p < 0.05, p < 0.01 and p < 
0.001, respectively. 
 
Upregulated 
genes 
 
Downregulated 
genes 
 Muscular function Name Fold Name  Fold 
 
Tnni1 2.18x** Alcam -2.37x* 
 
Tnnc1 2.49x** Actg2 -2.21x* 
 
Myh10 2.40x** Cxcr4 -2.20x** 
 
Tnnt2 3.26x** Etv1 -4.51x*** 
 
Tnnt3 2.17x** Gja1 -2.31x* 
 
Acta1 2.33x** Lama2 -4.41x** 
 
Actn3 2.62x* Itgb3 -4.48x** 
 
Atp1a2 2.11x* Musk -3.63x* 
 
Artn 2.53x* Mef2c -2.51x** 
 
Cspg4 3.52x** Met -2.60x* 
 
Cd34 5.81x** Mbnl3 -3.36x** 
 
Flnb 2.36x* Robo2 -5.08x** 
 
Kif5c 3.38x** Robo1 -4.63x** 
 
Myom2 2.42x* Sema5a -2.01x* 
 
Mylpf 2.32x** Tns1 -1.94x* 
 
Myf5 2.18x* Tns3 -2.29x** 
 
Mospd2 2.08x** 
  
 
Prkca 2.42x** 
  
 
Pdpn 2.78x** 
  
 
Tnc 5.08x** 
  
 
Unc5c 1.03x* 
  Lipid metabolism Stard4 2.44x** Acox2 -2.53x* 
 
Hmgcs1 3.38x** Cerk -2.37x** 
 
Ldlr 3.08x*** Il1rn -4.33x** 
 
Hsd17b7 4.56x** Pcx -2.60x** 
 
Hmgcr 2.26x* Prkar2b -3.65x* 
 
Acot10 2.16x** Pla2g7 -6,49x** 
 
Cyp51 3.43x** Plcb1 -3,96x** 
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Dhcr7 2.30x* 
  
 
Dhcr24 2.05x* 
  
 
Idi1 3.99x** 
  
 
Lss 2.84x** 
  
 
Nsdhl 2.19x** 
  
 
Pmvk 2.64x* 
  
 
Pcsk9 2.96x** 
  
 
Sc4mol 3.25x** 
  
 
Sc5d 2.26x** 
  
 
Tm7sf2 2.89x** 
  Alox5 2.25x* 
   Lass4 2.55x* 
   Ptgis 2.52x* 
   Pcyt2 2.18x* 
   Smpd3 2.04x* 
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Table 2. List of lipid compound used to modulate PARP2 expression 
Name Human 
reference/therapeutic 
range 
Concentration in 
the study 
Reference 
Medroxyprogesterone-
acetate (MPA) 
up to 7 nM 30 nM [71] 
Tibolone 32 - 48 nM 30 nM [71] 
Dexamethasone (DEX) 20,4 µM 10 µM [71] 
Cholic acid (CA) 0.48 – 2 µM 2 µM [72] 
Chenodeoxycholic acid 
(CDCA) 
0.32 – 2.2 2 µM 2 2 µM [72] 
Lithocholic acid (LCA) 10 – 50 nM 50 nM [72] 
Deoxycholic acid (DCA) 0.7 – 1 µM 1 µM [72]  
Ursodeoxycholic acid 
(UDCA) 
100 – 300 nM 300 nM [72] 
Cholestanol (CHOL) 9.26 ± 5.4 µM 14 µM [73] 
Trans-
dehydroepiandrosterone 
(DHEA) 
male: 0.4 – 13.5 µM 
female: 0.3 – 11 µM 
11 µM [74] 
Dihydrotestosterone (DHT) 0.7 – 2.63 nM 2.6 nM [75] 
Testosterone (TEST) male: 9.9 – 27.8 nM 
female: 0.2 – 2.9 nM 
9.9 nM [74] 
Estradiol (E2) male: 7.6 – 42.6 ng/L 
female: 8.5 – 498 ng/L 
0.15 nM [74] 
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Table 3. Primers used in the study 
Primer 
name 
Forward Reverse 
Parp2 GGAAGGCGAGTGCTAAATGAA  AAGGTCTTCACAGAGTCTCGATTG 
Srebp1 ACATCGAAGACATGCTCCAGC CCAGAGAAGCAGAAGAGAAGCTC 
Srebp2 GCAACTTTGTAGCTCCTTCCCTG TGGTGGGGTAGGAGAGACTTTG 
Hmgcr TGGAGATCATGTGCTGCTTC AACTCTGGCAAAATGGCTGA 
Acaca CACATGAGATCCAGCATGTCTG   TCATAAGACCACCGACGGATAG  
Acyl CACTCAGGCTTTCTCGAAGAG   TGATTAACTGGTCTGGCTTGAC  
Scd2 CCACATACTGCAAGAGATCTCTGG  CTCCAGACGTACTCCAGCTTGG  
Ldlr CGGAGTTGCAGCAGAAGACTC TCCAGGAGTCAGGAATGCATC  
Fdps CCAAGAAAAGCAGAATTTCATCC  GAAGACTCTCAGCATCCTGTTTC 
Cyp7a1 GGAAAGTAGGTGAACCTCCTTTGG CCGTGACATAAGACTTTGTGGTATG 
Star ATCGGGAGGGGTGGTAGTCA TCCCCTGTTCGTAGCTGCTG 
Hsd17b11 TCTTGCTGGCTTACTGCTCCA TCCTGTTCGTCCCAAGGCAG 
Srd5a1 ACGTACCACTCACCCTTCGC TGGGAAGCCAAGGGAAGGTG 
Srd5a2 GACATGCGGTTTAGCGTCGG AAGCCACCTTGTGGGATCCTG 
18S GGGAGCCTGAGAAACGGC GGGTCGGGAGTGGGTAATTTT 
Cyclophilin TGGAGAGCACCAAGACAGACA TGCCGGAGTCGACAATGAT 
Gapdh CAAGGTCATCCATGACAACTTTG GGCCATCCACAGTCTTCTGG 
Insig1a TCACAGTGACTGAGCTTCAGCA TCATCTTCATCACACCCAGGAC 
Scap ATTTGCTCACCGTGGAGATGTT GAAGTCATCCAGGCCACTACTAATG 
Sp1 GCTACATCGACCTGACTGAGTGT TGGTAAATAGGGTCGCCACTCAG 
Sp2 TTTTGGAATGGTGTTTGGCGTGA CTGCAGCGAAGAAGTAAGTCAGC 
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Table 4. Antibodies used in the study 
* indicates validated antibodies from the https://www.antibodypedia.com/ site. 
 
Antibody Company Dilution 
PARP2 Alexis, Lausen, Switzerland (ALX-210-899)* 1:1000 
SREBP1 Santa Cruz, Santa Cruz, CA, USA (sc-8984) 1:1000 
SREBP2 Santa Cruz, Santa Cruz, CA, USA (sc-5603) 1:1000 
HMGCR Abcam, Cambridge, UK (ab174830) 1:1000 
Actin Sigma, Saint Louis, MO, USA (A3854) 1:20000 
SREBP1 
(Fig. 3D) 
Santa Cruz, Santa Cruz, CA, USA (2A4) 1:1000 
SREBP2 
(Fig. 3D) 
Santa Cruz, Santa Cruz, CA, USA (1C6) 1:1000 
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Table 5. Human CDR ChIP-seq datasets 
Cell line GEO ID Treatment Pubmed ID 
GM10855 GSM558630 nontr 
20736230 
GM10855 GSM558631 nontr 
GM10855 GSM558632 D3 
GM10855 GSM558633 D3 
GM10861 GSM558634 nontr 
GM10861 GSM558635 nontr 
GM10861 GSM558636 D3 
GM10861 GSM558637 D3 
THP1 GSM2371448 veh 
28870774 
THP1 GSM2371449 D3 
THP1 GSM2371450 veh 
THP1 GSM2371451 D3 
THP1 GSM2371452 veh 
THP1 GSM2371453 D3 
LX2 GSM934612 nontr 24787735 
LNCaP GSM1576449 D3 
no 
reference 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
29 
 
 
Table 6. Mouse VDR ChIP-seq data 
Cell line GEO ID Treatment Pubmed ID 
Intestine GSM1694857 veh 
26041780 
Intestine GSM1694858 veh 
Intestine GSM1694859 veh 
Intestine GSM1694860 D3 
Intestine GSM1694861 D3 
Intestine GSM1694862 D3 
MC3T3-E1 GSM1027472 veh 
24891508 
MC3T3-E1 GSM1027473 D3 
MSC GSM2104114 veh 
27402842 
MSC GSM2104115 veh 
MSC GSM2104116 D3 
MSC GSM2104117 D3 
MSC osteogenic GSM2104150 veh 
27402842 
MSC osteogenic GSM2104152 D3 
MSC adipogenic GSM2104218 veh 
MSC adipogenic GSM2104220 D3 
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Highlights 
 
1. The genetic deletion of poly(ADP-ribose)-2 (PARP2) induces characteristic changes 
in the lipidome. 
 
2. In PARP2 knockout mice SREBP1 and SREBP2 is overexpressed in skeletal muscle 
leading to higher muscular cholesterol biosynthesis. 
 
3. Higher muscular cholesterol is shunted towards muscular dihydrotestoesterone 
synthesis, but is not translated into systemic increases in dihydrotestosterone levels. 
 
4. The muscles from PARP2 knockout mice are stronger as compared to the ones 
derived from wild type littermates. 
 
5. The expression of PARP2 is regulated by cholesterol derivatives. 
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